283 related articles for article (PubMed ID: 35119664)
21. The Assessment of Estrogen Receptor Status and Its Intratumoral Heterogeneity in Patients With Breast Cancer by Using 18F-Fluoroestradiol PET/CT.
Yang Z; Sun Y; Xu X; Zhang Y; Zhang J; Xue J; Wang M; Yuan H; Hu S; Shi W; Zhu B; Zhang Y
Clin Nucl Med; 2017 Jun; 42(6):421-427. PubMed ID: 28221191
[TBL] [Abstract][Full Text] [Related]
22.
Nienhuis HH; van Kruchten M; Elias SG; Glaudemans AWJM; de Vries EFJ; Bongaerts AHH; Schröder CP; de Vries EGE; Hospers GAP
J Nucl Med; 2018 Aug; 59(8):1212-1218. PubMed ID: 29602822
[TBL] [Abstract][Full Text] [Related]
23. Pharmacodynamic imaging guides dosing of a selective estrogen receptor degrader.
Heidari P; Deng F; Esfahani SA; Leece AK; Shoup TM; Vasdev N; Mahmood U
Clin Cancer Res; 2015 Mar; 21(6):1340-7. PubMed ID: 25609068
[TBL] [Abstract][Full Text] [Related]
24. Clinical and economic outcomes of adding [18F]FES PET/CT in estrogen receptor status identification in metastatic and recurrent breast cancer in the US.
Munter-Young R; Fuentes-Alburo A; DiGregorio N; Neeser K; Gultyaev D
PLoS One; 2024; 19(5):e0302486. PubMed ID: 38743917
[TBL] [Abstract][Full Text] [Related]
25. Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition.
Boers J; Venema CM; de Vries EFJ; Glaudemans AWJM; Kwee TC; Schuuring E; Martens JWM; Elias SG; Hospers GAP; Schröder CP
Eur J Cancer; 2020 Feb; 126():11-20. PubMed ID: 31891878
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of tumour heterogeneity by
Liu C; Hu S; Xu X; Zhang Y; Wang B; Song S; Yang Z
Breast Cancer Res; 2022 Aug; 24(1):57. PubMed ID: 36028895
[TBL] [Abstract][Full Text] [Related]
27. Biodistribution of
Iqbal R; Yaqub M; Oprea-Lager DE; Liu Y; Luik AM; Beelen AP; Schuit RC; Windhorst AD; Boellaard R; Menke-van der Houven van Oordt CW
J Nucl Med; 2022 May; 63(5):694-699. PubMed ID: 34446451
[TBL] [Abstract][Full Text] [Related]
28. In vivo imaging of brain estrogen receptors in rats: a 16α-18F-fluoro-17β-estradiol PET study.
Khayum MA; de Vries EF; Glaudemans AW; Dierckx RA; Doorduin J
J Nucl Med; 2014 Mar; 55(3):481-7. PubMed ID: 24481026
[TBL] [Abstract][Full Text] [Related]
29. Clinical Potential of Estrogen and Progesterone Receptor Imaging.
Linden HM; Peterson LM; Fowler AM
PET Clin; 2018 Jul; 13(3):415-422. PubMed ID: 30100079
[TBL] [Abstract][Full Text] [Related]
30. Utility of
Lin FI; Gonzalez EM; Kummar S; Do K; Shih J; Adler S; Kurdziel KA; Ton A; Turkbey B; Jacobs PM; Bhattacharyya S; Chen AP; Collins JM; Doroshow JH; Choyke PL; Lindenberg ML
Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):500-508. PubMed ID: 27872957
[TBL] [Abstract][Full Text] [Related]
31. 18F-Fluoroestradiol PET: Current Status and Potential Future Clinical Applications.
Liao GJ; Clark AS; Schubert EK; Mankoff DA
J Nucl Med; 2016 Aug; 57(8):1269-75. PubMed ID: 27307345
[TBL] [Abstract][Full Text] [Related]
32. Improved Estrogen Receptor Assessment by PET Using the Novel Radiotracer
Paquette M; Lavallée É; Phoenix S; Ouellet R; Senta H; van Lier JE; Guérin B; Lecomte R; Turcotte ÉE
J Nucl Med; 2018 Feb; 59(2):197-203. PubMed ID: 28798032
[TBL] [Abstract][Full Text] [Related]
33. Women's Health Update: Growing Role of PET for Patients with Breast Cancer.
Ulaner GA; Vaz SC
Semin Nucl Med; 2024 Mar; 54(2):247-255. PubMed ID: 38365547
[TBL] [Abstract][Full Text] [Related]
34.
Kumar M; Salem K; Michel C; Jeffery JJ; Yan Y; Fowler AM
J Nucl Med; 2019 Sep; 60(9):1247-1252. PubMed ID: 30850489
[TBL] [Abstract][Full Text] [Related]
35. Fully automated radiosynthesis and quality control of estrogen receptor targeting radiopharmaceutical 16α-[
Wang M; Glick-Wilson BE; Zheng QH
Appl Radiat Isot; 2020 Jun; 160():109109. PubMed ID: 32174461
[TBL] [Abstract][Full Text] [Related]
36. Estrogen Receptor-Targeted and Progesterone Receptor-Targeted PET for Patients with Breast Cancer.
Ulaner GA; Fowler AM; Clark AS; Linden H
PET Clin; 2023 Oct; 18(4):531-542. PubMed ID: 37270377
[TBL] [Abstract][Full Text] [Related]
37. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer.
Dehdashti F; Mortimer JE; Trinkaus K; Naughton MJ; Ellis M; Katzenellenbogen JA; Welch MJ; Siegel BA
Breast Cancer Res Treat; 2009 Feb; 113(3):509-17. PubMed ID: 18327670
[TBL] [Abstract][Full Text] [Related]
38. Clinical production, stability studies and PET imaging with 16-alpha-[18F]fluoroestradiol ([18F]FES) in ER positive breast cancer patients.
Kumar P; Mercer J; Doerkson C; Tonkin K; McEwan AJ
J Pharm Pharm Sci; 2007; 10(2):256s-265s. PubMed ID: 17718929
[TBL] [Abstract][Full Text] [Related]
39. Comparison of 18F-FES, 18F-FDG, and 18F-FMISO PET Imaging Probes for Early Prediction and Monitoring of Response to Endocrine Therapy in a Mouse Xenograft Model of ER-Positive Breast Cancer.
He S; Wang M; Yang Z; Zhang J; Zhang Y; Luo J; Zhang Y
PLoS One; 2016; 11(7):e0159916. PubMed ID: 27467716
[TBL] [Abstract][Full Text] [Related]
40.
Grabher BJ
J Nucl Med Technol; 2023 Sep; 51(3):188-193. PubMed ID: 37433673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
